Search

Displaying results 2881 - 2890 of 7706 in total
  1. Drug

    ATP

    go.drugbank.com/drugs/DB00171
    InvestigationalNutraceutical

    An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter.

  2. Drug

    Ethylestrenol

    go.drugbank.com/drugs/DB01493
    ApprovedWithdrawn

    An anabolic steroid with some progestational activity and little androgenic effect. [PubChem]

  3. Drug

    CRA-028129

    go.drugbank.com/drugs/DB05951
    Experimental

    CRA-028129 is cathepsin S inhibitor which is under investigation for the treatment of psoriasis.

  4. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.[L8063]

  5. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and

  6. Drug

    3-Methylfentanyl

    go.drugbank.com/drugs/DB01571
    ExperimentalIllicit

    3-Methylfentanyl is an opioid analgesic and is an analog of the potent opioid, fentanyl. 3-Methylfentanyl is one of the most powerful opioid drugs sold illegally and is estimated to be between 400-6000

  7. Drug

    Colestilan chloride

    go.drugbank.com/drugs/DB11634
    ApprovedWithdrawn

    Colestilan is an ingredient in the EMA-withdrawn product BindRen.

  8. Drug

    Nomegestrol

    go.drugbank.com/drugs/DB11636
    Approved

    Nomegestrol is an ingredient in the EMA-authorised product Zoely.

  9. Drug

    Temocapril

    go.drugbank.com/drugs/DB08836
    Investigational

    Temocapril can also be used in hemodialysis patients without risk of serious accumulation.

  10. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    [A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ.[L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant]. … Daridorexant was designed via an intensive drug discovery program to improve the potency and maximize the duration of action while minimizing next-morning residual activity.